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Keeping Our Drinking Water Free of Pharmaceuticals: A Joint Action Plan
Introduction
Following a 2008 investigation, the Associated Press revealed that many different types
of pharmaceuticals, including antibiotics, anti-convulsants, mood stabilizers and sex hormones
are found in drinking water across the country.1 The study took place over the course of five
months, and tested the drinking water of twenty-four major metropolitan areas.2 Though
wastewater is treated before it enters the rivers and reservoirs, and is often treated a second time
before it becomes drinking water, drug residues remain.3 As of 2008, the federal government had
not set any standards or limits for drugs in the water;4 all tap water that tested positive for drugs
still met federal drinking water standards.5
Recent studies have shown that the increase of pharmaceutical chemicals6 in the waters
has caused genetic mutations in populations of fish. Several studies conducted in the United
States have found that fish experience “significant neurological and physiological changes” as a
result of hormones and antidepressants being disposed of in the water.7 For example, a
Maryland study determined that male bass produced “both sperm and eggs” as a result of

1

Jeff Donn et al., Drugs Found in Drinking Water, USA TODAY (Mar. 10, 2008), available at
http://usatoday30.usatoday.com/news/nation/2008-03-10-drugs-tap-water_N.htm.
2
Id. The areas that tested positive for pharmaceuticals in the tap water included Atlanta (GA), Cincinnati (OH),
Columbus (OH), Indianapolis (IN), Las Vegas (NV), Long Beach (CA), Louisville (KY), Milwaukee (WI),
Minneapolis (MN), New Orleans (LA), New Jersey, Philadelphia (PA), Portland (OR), Riverside County (CA), San
Diego (CA), San Francisco (CA), Southern California, Tucson (AZ), Washington D.C.
3
Id.
4
Id.
5
Id.
6
The increase in the amount of chemicals in the water also includes chemicals from personal care products. Toby
K.L. Morgan, Down the Drain: Pharmaceutical Waste Disposal in the United States, 22 Fordham Envtl. L. Rev.
393 (Spring 2011). The disposal of personal care products into the water is beyond the scope of this paper.
7
Tierney Christenson, Fish on Morphine: Protecting Wisconsin’s Natural Resources Through a Comprehensive
Plan for Property Disposal of Pharmaceuticals, 2008 Wis. L. Rev. 141, 143 (citing Juliet Eilperin, Pharmaceuticals
in Waterways Raise Concerns: Effect on Wildlife, Humans Questioned, WASH. POST, June 23, 2005, A3).
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increased estrogen in the water.8 The researchers believed that the source of the estrogen was
birth control pills that had been flushed.9 These chemicals also have the potential to cause harm
to human health. Some scientists have found links between pharmaceutical pollutants and earlier
puberty in children.10 A study in the United Kingdom found a link between hormones in the
environment, a lower sperm count and the development of breasts in men.11 While the extent of
the effect on human health remains unknown,12 the effects will vary based on the type of drug
and the concentration in which humans are exposed. In light of the results of these recent
studies, the disposal of pharmaceuticals in the water is increasingly becoming a public health
concern.
It was originally believed that the best way to dispose expired or unused prescription
pharmaceuticals was by flushing them down the toilet, to keep them out of the hands of children
and off of the black market.13 Recently, as drug residue has been discovered in drinking water
nationwide, a number of states have proposed legislation to regulate the disposal of
pharmaceuticals and prevent their disposal in drinking water sources.14 Despite these attempts to

8

Id. (citing George J. Mannina, Jr., Medicines and the Environment: Legal and Regulatory Storms Ahead?, LEGAL
BACKGROUNDER, Mar. 24, 2006).
9
Id. However, a 2011 study determined that flushed birth control pills account for less than one percent of the
estrogen found in the water. About 90 percent of the estrogen found in the water was from hormones given to
livestock. American Chemical Soc’y, Don't blame the pill for estrogen in drinking water, SCIENCEDAILY (Feb. 15,
2011), available at http://www.sciencedaily.com/releases/2010/12/101208125813.htm.
10
Darshak M. Sanghavi, Preschool Puberty, and a Search for the Causes, N.Y. TIMES, Oct. 17, 2006.
11
Elizabeth Royte, Drugging the Waters: How an Aging Population and Our Growing Addiction to
Pharmaceuticals May be Poisoning Our Rivers, OnEarth 26, 30 (Fall 2006), available at
http://www.nrdc.org/onearth/06fal/waters1.asp.
12
World Health Org., Information Sheet: Pharmaceuticals in Drinking Water, available at
http://www.who.int/water_sanitation_health/emerging/info_sheet_pharmaceuticals/en/ (last accessed Dec. 4, 2013).
13
Louise Slaughter, Secure Prescription Drug Take-Back Programs Protect Our Children, our Waterways, and the
Public: Sign on to H.R. 293.
14
See Citizens Campaign for the Env’t., Pharmaceutical Disposal, (July 16, 2013) available at
http://www.citizenscampaign.org/campaigns/pharmaceutical-disposal.asp (last accessed Dec. 4, 2014). For example,
in Suffolk County New York, all hospitals, nursing home facilities, and long term care facilities must submit an
annual plan for the safe disposal of unused or expired medications. Suffolk Cnty. Dep’t of Health Servs. Resolution
#1402 (Mar. 22, 2011).

3

Melissa Rifai
legislate, the “flushing method” is still the most widely used and accepted method of drug
disposal,15 leading to the increasing problem of drug residue in drinking water.
Further, current federal law is inadequate to regulate the disposal of pharmaceuticals
because neither the Food and Drug Administration (“FDA”) nor the Environmental Protection
Agency (“EPA”) has promulgated rules or regulations expressly prohibiting the disposal of
pharmaceuticals in the water; the FDA regulates pharmaceuticals as a health concern, and gives
the environment little consideration, while the EPA regulates without expressly prohibiting
disposal of drugs in the water. Thus, neither the FDA nor the EPA is singularly regulating the
disposal of pharmaceuticals in the water, leading to a fragmented and ineffective regulatory
scheme, and a growing problem of pharmaceutical waste in the water. It is imprudent for the
EPA and FDA to continue without regulating the disposal of pharmaceuticals in the water,
because a wait-and-see approach could have harmful effects on human and environmental health.
This paper proposes a scheme in which the Environment Protection Agency and the Food
and Drug Administration work together to re-conceptualize disposal of expired or unused
pharmaceuticals with the goal of reducing the amount of pharmaceuticals disposed of in the
water. This paper begins with a background section, which describes how pharmaceutical waste
is generated, and the issues caused by pharmaceutical waste disposal in the nation’s waters. The
following section provides a brief overview of the current regulatory framework and why it is
inadequate to regulate the disposal of pharmaceuticals in the water. Section three describes
solutions that have been proposed to curb the disposal of pharmaceuticals in the water. The final
section proposes a joint action plan in which the EPA and FDA expand the scope of their
respective regulatory provisions to include regulation of pharmaceutical waste disposal, and

15

The term “drugs” will be used interchangeably with the word “pharmaceuticals” throughout.
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work together to require an environmental impact assessment of the impact of disposal for all
new drugs before approval to market. The outcome of the impact assessment will be to
determine the most environmentally friendly way to dispose of the new drug. Proposing joint
federal action, rather than state action, will create a uniform system of disposal with the goal of
reducing the amount of pharmaceutical waste in our nation’s waters.
I. Pharmaceutical Waste
The use of pharmaceuticals has been advantageous to modern society.16 For example, in
1995, the life expectancy of a person who was HIV positive was 10 years.17 Due to the
introduction of antiretroviral pharmaceuticals, the life expectancy had risen to 22.5 years by
2008.18 Also, antibiotic use on livestock has been critical to preventing, controlling and treating
disease in livestock, which subsequently reduces animal to human transmission of bacteria.19
However, for as long as pharmaceuticals have been prevalent, society has been faced with the
problem of proper disposal practices. Disposal of pharmaceuticals in the water has long been a
widespread practice; a 1970 study found heart medication, pain relief medication and birth
control pills in wastewater.20 As the volume and quantity of pharmaceutical consumption
increases,21 the concentration of pharmaceutical residue in the water also increases.

16

World Health Org. Work Group Report, Pharmaceuticals in Drinking Water (2012).
Linda Dahlstrom, Aging with AIDS: Living Longer, Living with Loss (2011), available at
http://www.nbcnews.com/id/43230322/#.Up1kN421_4g (last accessed Dec. 4, 2013).
18
Id.
19
Animal Health Institute, Animal Antibiotics (2013), available at http://www.ahi.org/issues-advocacy/animalantibiotics/ (last accessed Dec. 4, 2013).
20
World Health Org. Work Group Report, supra n. 16.
21
Health at a Glance 2011: OECD Indicators, available at http://www.oecd-ilibrary.org/sites/health_glance-2011en/04/11/index.html;jsessionid=3dln9sdrovedm.delta?contentType&itemId=/content/chapter/health_glance-201139-en&containerItemId=/content/serial/19991312&accessItemIds=/content/book/health_glance-2011en&mimeType=text/html (last accessed Dec. 4, 2013).
17
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A. Pharmaceutical Waste Defined
How the federal government defines waste determines whether federal law regulates the
disposal a particular compound. “Waste” generally refers to “any discarded material” that is not
otherwise excluded.22 Discarded material is defined as any material, which is “abandoned,”
“recycled,” or “considered inherently waste-like.”23 Though expired or unused pharmaceuticals
seemingly fall within this scope, most pharmaceutical compounds are not included in federal
definitions of waste, resulting in unclear and non-uniform regulation of disposal of unused
pharmaceuticals. Further, certain pharmaceutical compounds, such as hormones from the
disposal or excretion of oral contraceptives, are not even included in the federal definitions of
pharmaceutical waste. So long as disposed pharmaceuticals are not regulated under the federal
definition of waste, it is unlikely that there will be a uniform implementation of disposal
requirements nationwide. Therefore, a first step in the process of regulating pharmaceutical
waste is defining it.
The EPA regulates the disposal of a number of different types of waste, including solid
waste, medical waste, and hazardous waste. The definition of medical waste does not expressly
include pharmaceuticals.24 Hazardous waste can be categorized as either listed waste or
characteristic waste. Listed waste is listed in four categories (P, F, K, U) and pharmaceuticals
can be found on both the P and U lists,25 but only a few pharmaceuticals are included on these
lists. The P-list contains “commercial chemicals that are acutely toxic” meaning that they can

22

40 C.F.R. 261.2
Id.
24
Medical Waste Tracking Act, H.R. 3515 (1988) (amendment to the Solid Waste Disposal Act).
25
Healthcare Envtl. Res. Ctr., Managing Pharmaceutical Waste: A 10-Step Blueprint for Healthcare Facilities in
the United States 14 (August 2008), available at http://www.hercenter.org/hazmat/tenstepblueprint.pdf
23
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cause death or irreversible illness at low doses.26 The U-list has less stringent toxicity
requirements.27 Chemical compounds found on the P or U list are regulated by the Resource
Conservation and Recovery Act (“RCRA”) Subtitle C Generator requirements.28 A
pharmaceutical is only covered under this list if the sole active ingredient of the drug is listed.29
Characteristic wastes are regulated because they exhibit certain hazardous properties –
ignitability,30 corrosivity,31 reactivity,32 and toxicity.33 Generators of hazardous waste intended
for disposal must determine whether the waste has any of these characteristics.34 Waste that
neither is listed nor exhibits one of the mentioned characteristics is considered solid waste and
should be discarded according to state and local regulations.35 Only in some states will these
regulations include medical waste.36 The number of P-listed and U-listed pharmaceuticals is
small, and the majority of pharmaceuticals do not exhibit one or more of the mentioned
characteristics, leaving the majority of disposed pharmaceuticals exempt from federal regulation
as hazardous waste. Thus, oftentimes, a state or local government regulates the disposal of
pharmaceutical waste. Differences in definitions of pharmaceutical waste, such as defining it as
hazardous waste or medical waste, leaves unclear regulations that differ between states.

26

See generally Health Env’t. Res. Ctr., Hazardous Waste Determination, available at
http://www.hercenter.org/hazmat/hazdeterm.cfm#listed for discussion of RCRA listed hazardous waste and its
application to healthcare facilities.
27
Id.
28
Envtl. Prot. Agency, Hazardous Waste Generators, available at
http://www.epa.gov/waste/hazard/generation/index.htm (last accessed Dec. 4, 2013).
29
Id.
30
Ignitability refers to whether the waste presents a fire hazard under normal storage, disposal or transportation. 10
Step Blueprint, supra n. 25 at 20.
31
Corrosivity refers to waste which is highly acidic, with a pH less than or equal to two, or highly basic, with a pH
of greater than or equal to 12.5. Id. at 22.
32
Reactivity refers to wastes, which are unstable under normal conditions. Id. at 24.
33
Toxicity refers to the point at which chemicals and heavy metals exceed the stated limits. Id. at 24; A waste need
only have one of these characteristics to be considered hazardous. Id. at 20.
34
Id.
35
Id.
36
Id. Regulated medical waste is defined by the state or locality. Id. at 26.
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However, pharmaceutical residue in the water does not respect jurisdictional boundaries, leaving
even the states with stringent disposal requirements vulnerable to pharmaceutical waste
pollution. In order for a uniform federal regulation to be effective, a discrete definition of
pharmaceutical waste must be promulgated.
The FDA has promulgated federal guidelines for consumer disposal of pharmaceuticals.37
These guidelines are not binding, and are intended only to direct domestic consumers to proper
disposal of small quantities of unused medications.38 However, as discussed in further detail
below, humans and animals create the majority of pharmaceutical waste through industrial
disposal, hospital disposal, and excretion.39 Thus, non-binding guidelines for the disposal of
small quantities of domestic pharmaceutical waste is not sufficient to curb the growing problem
of pharmaceutical waste in the water as it does not stop pollution from the biggest sources.
Without the express inclusion of pharmaceutical waste in a federally regulated waste disposal
statute, the current definitions of solid waste, medical waste, and hazardous waste are inadequate
to properly regulate the disposal of pharmaceuticals.
B. Generation of Pharmaceutical Waste
Identifying the largest generators of pharmaceutical waste is necessary for determining
which industries should be included within the scope of the reformed regulation. Pharmaceutical
waste is generated by a variety of activities ranging from patient care in the hospital setting to
outpatients’ disposal of personal medications that are unused or expired.40 Hospitals are a
significant contributor to the amount of pharmaceutical waste generated annually. In fact, in an

37

Food and Drug Admin., How to Dispose of Unused Medicines, available at
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm101653.htm (last accessed Dec. 4, 2013).
38
Id.
39
10-Step Blueprint, supra n. 25.
40
Id.
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EPA analysis of nationwide hospital pharmaceutical disposal, the EPA found that hospitals
dispose of 9,700 tons of pharmaceutical waste per year.41 For a long time, hospitals disposed of
their unused or expired pharmaceuticals by flushing them down the toilet.42 Other contributors to
pharmaceutical waste may include illicit drug laboratories, which frequently dispose of “raw
products and intermediaries” by flushing them down the toilet.43
Pharmaceutical waste also enters the environment through sewage treatment facilities,44
and via burial in landfills.45 Human consumption and excretion contributes to this because
humans do not fully metabolize pharmaceuticals.46 Similarly, excretion of medications and other
pharmaceuticals given to pets and livestock contribute, though less significantly, to the amount
of pharmaceutical waste.47 One study found that as little as seven percent of “active drug
compounds” found in sewage water was removed in the sewage treatment process.48 Thus, the
majority of “active drug compounds” remain in the water. While the disposal of pharmaceuticals
into the water through the human excretory process is unintentional, the intentional disposal of
pharmaceuticals or other over-the-counter medications into the waste systems also occurs.49

41

Down the Drain, 22 Fordham Envtl. L. Rev. at 401-402 (citing Econ., Methods, & Risk Analysis Div., Off. Of
Solid Waste, Envtl. Prot. Agency, Assessment of the Potential Costs, Benefits and Other Impacts of Adding
Pharmaceuticals to the Universal Waste Rule as Proposed by ES-1 (2008) (on file with author)).
42
Christian G. Daughton, Cradle-to-Cradle Stewardship of Drugs for Minimizing Their Environmental Disposition
While Promoting Human Health. II. Drug Disposal, Waste Reduction, and Future Directions, 111 Envtl. Health
Persp. 775, 780 (May 2003).
43
Christian G. Daughton & Thomas A. Ternes, Pharmaceuticals and Personal Care products in the Environment:
Agents of Subtle Change?, 107 Envtl. Health Persp. 907, 908 (Dec. 1999).
44
Id. at 912.
45
Id.
46
Christian G. Daughton, Pharmaceuticals and Personal Care Products in the Environment: Overarching Issues
and Overview, in Pharmaceuticals and Personal Care Products in the Environment: Scientific and Regulatory Issues
2, 11 (Christian G. Daughton & Tammy L. Jones-Lepp, eds., 2001).
47
Melanie Leitman (Student Comment), Water Rx the Problem of Pharmaceuticals in our Nation’s Waters, 29
UCLA J. Envtl. L. & Pol’y 395. (citing Bethany Halford, Side Effects, Chem & Eng’g News, Feb. 25, 2008).
48
Id. at 399 (citing Envtl. Prot. Agency, Frequent Questions – Pharmaceuticals and Personal Care Products,
available at http://www.epa.gov/ppcp/faq.html).
49
Stephen E. Musson & Timothy G. Townsend, Pharmaceutical Compound Content of Municipal Solid Waste, 162
Hazardous Materials 730 (2009).
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C. Problems with disposing of pharmaceuticals in the water
The effects of pharmaceutical residue on human health, animal health, and environmental
health have been the subject of a number of scientific studies. These studies have returned
sobering results that highlight the problems posed by pharmaceutical waste in the water. These
effects will be exacerbated if the practice of disposing of pharmaceuticals in the water remains
unchecked.
(i)

Public Health

Pharmaceuticals, by nature, elicit physiological change in humans.50 While the exact
effect on humans of pharmaceuticals in the waters remains largely unknown,51 a number of
studies have found a link between drugs in the water and physiological change in humans. For
example, a United Kingdom study found a link between the presence of hormones in the water
with lower sperm counts and the development of breasts in men.52
Pharmaceuticals in the water are of particular concern to vulnerable populations, such as
pregnant women, young children, and people with compromised immune systems. One study
cited cases in which children were exhibiting premature signs of puberty and linked this change
to pharmaceuticals in the water.53 People with certain drug allergies may also be vulnerable.

50

Water Rx, supra n. 47 at 204.
Darshak M. Sanghavi, Preschool Puberty & A Search for the Causes, N.Y. Times (Oct. 17, 2006) n.1. available at
http://www.nytimes.com/2006/10/17/science/17puberty.html?pagewanted=all&_r=0.
52
Christopher T. Nidel, Regulating the Fate of Pharmaceutical Drugs: A New Prescription for the Environment, 50
Food & Drug L. J. 81, 84 (2003).
53
Darshak M. Sanghavi, Preschool Puberty & a Search for the Causes, N.Y. Times (Oct. 17, 2006) n.1. available at
http://www.nytimes.com/2006/10/17/science/17puberty.html?pagewanted=all&_r=0.
51
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While current concentrations of pharmaceutical residue in drinking water are too low to elicit
allergic reactions,54 allergic reactions may manifest if the residue concentration increases.55
Finally, scientists have expressed concerns about antimicrobial bacterial resistance.56 A
number of disease-causing bacteria can be found in the water.57 Scientists are concerned that if
antibiotics are being disposed of in the water, the bacteria will become resistant to these
antibiotics.58 If these drug-resistant bacteria cause disease in humans, conventional drug
treatment will be ineffective.59 Drug resistance is not a problem that is unique to water
pollution,60 but the consequences of drug-resistant waterborne pathogens could be severe.
(ii)

Environmental & Animal Health

The significant amount of pharmaceutical waste found in the water has distinct effects on
environmental and animal health. A number of studies have been conducted that document the
considerable changes to the physiological health of fish in contaminated waters. As a result of
the amount of estrogen found in the water, male fish are being feminized and producing egg yolk
proteins, which is normally produced by female fish.61 Scientists have found that the increased
feminization of the male fish “dramatically decreased” the population of certain species.62

54

Alicia Anderson et al., Public Health Consequences of Use of Antimicrobial Agents in Food Animals in the United
States, 9 Microbial Drug Resistance 373 (2003).
55
Water Rx, supra n. 47 at 405.
56
Id.
57
World Health Org. Water Sanitation Health, Waterborne Pathogens, available at
http://www.who.int/water_sanitation_health/gdwqrevision/watpathogens.pdf
58
Water Rx, supra n. 47 at 405.
59
Id.
60
See generally, Nat’l. Instit. of Allergy and Infectious Disease, Antimicrobial Drug Resistance, available at
http://www.niaid.nih.gov/TOPICS/ANTIMICROBIALRESISTANCE/Pages/default.aspx (last accessed Dec. 4,
2013).
61
Jeff Donn et al., Drugs Found in Drinking Water, supra n. 1.
62
Water Rx, supra n. 47 at 407-08. “Scientists observed the fathead minnow present in the law and found that the
feminization of male minnow resulted in a dramatically decreased population of the species. At the end of a fouryear period, according to the study, ‘the fish had all but disappeared from the lake.’ Interestingly, three years after
the scientists ceased adding the estrogen, the targeted species population rebounded.” (citing Bethany Halford, Side
Effects, Chem & Eng’g News, Feb. 25, 2008).
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One study from the University of Wisconsin introduced anti-cholesterol medication into
the water of a school of fathead minnows.63 The medication was introduced at a level “only
slightly higher” than what was currently found in Wisconsin’s streams.64 “[The minnows] were
sitting at the bottom of the tank, barely moving and barely breathing.”65 The study, intended to
run for a week, was discontinued after only 24 hours, because the minnows were “struggling to
survive.”66 The researchers expressed concern that the pharmaceuticals “are not only having an
effect on aquatic organisms, but on human populations as well.”67
(iii)

Pharmaceuticals in our drinking water

In the United States, the water contamination is not just at the surface.68 “Pharmaceuticals
also permeate aquifers69 deep underground.”70 Water tested from aquifers drawn from sites near
landfills and animal feedlots also had trace amounts of pharmaceuticals in it.71 These aquifers
source 40% of the nation’s water supply.72 Though water in the United States goes through both
disinfection and filtration processes before it becomes drinking water,73 pharmaceutical residue
is still found in finished drinking water. Researchers have estimated that about 41 million people
have been exposed to pharmaceutical residue in their drinking water.74 This problem will not

63

Fish on Morphine, supra n. 7, at 144. Study conducted by Rebecca D. Klaper, University of Wisconsin.
Id.
65
Juliet Eilperin, Pharmaceuticals in Waterways Raise Concern: Effect on Wildlife, Humans Questioned, supra n. 7.
66
Id.
67
Id.
68
Id.
69
“An aquifer is a body of saturated rock through which water can easily move.” See
http://imnh.isu.edu/digitalatlas/hydr/concepts/gwater/aquifer.htm (last accessed Dec. 4, 2013)
70
Jeff Donn et al., Drugs Found in Drinking Water, supra n. 1.
71
Id.
72
Id.
73
Sewage and Water Board, The Water Purification Process at the Carrollton Plant, available at
http://www.swbno.org/history_water_purification.asp; see also Eurotherm, The Water Purification Process,
available at http://www.eurotherm.com/industries/life-sciences/applications/water-purification/.
74
Water Rx, supra n. 47 at 397.
64
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resolve itself; federal or state action is necessary to reduce the amount of pharmaceutical residue
in drinking water.
II. Current Regulatory Framework
As explained above, current EPA and FDA regulations are inadequate to ensure safe
disposal of pharmaceutical waste. However, if the EPA and FDA are empowered to work
together to address this issue, they may be able to develop new regulations that lessen the
concentration of pharmaceutical waste in the water. To determine what changes are required, it is
important to understand the current regulatory framework. The following is an overview of the
existing regulations and the ways in which current statutes have the potential to address
pharmaceutical waste.
A. EPA
The Environmental Protection Agency is charged with enforcing statutes that direct
cleanliness standards for the nation’s water. The relevant provisions are: the Clean Water Act
which operates to reduce pollutants and contamination in the water,75 the Safe Drinking Water
Act76 and the Resource Conservation and Recovery Act77 which work to regulates the hazardous
waste in the water. Through these regulations, the EPA regulates hazardous waste in the water,
which could add more regulations to extend to the disposal of pharmaceutical waste in the water
if the scope of the regulations is expanded.
(i) Clean Water Act

75

33 U.S.C. § 1251.
42 U.S.C. § 300g-1.
77
42 U.S.C. § 6901.
76
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The Clean Water Act78 does not expressly prohibit the disposal of pharmaceutical waste
in the water, but does have the potential to address pharmaceutical contamination.79 “The Clean
Water Act establishes the basic structure for regulating discharges of pollutants into the waters of
the United States and regulating quality standards for surface waters.”80 The statute provides a
regulatory scheme for the discharge of pollutants into the water,81 regulating activities such as
industrial discharges, sewage treatment, concentrated animal feeding operations,82 aquaculture83
and other point source discharges.84 However, none of these sources are regulated for the
disposal of pharmaceuticals.
The Clean Water Act also includes a best available technology provision.85 This
provision requires the use of the best available technology economically achieve to further the
goal of eliminating discharge of all pollutants.86 This acts as a floor for the types of treatment
that must be used by dischargers of pollutants.87 The assessment of best available technology
includes a number of factors over which the EPA has the discretion to weigh.88 These factors are:

78

33 U.S.C. § 1251.
Water Rx, supra n. 47.
80
Envtl. Prot. Agency, Summary of the Clean Water Act, available at http://www2.epa.gov/lawsregulations/summary-clean-water-act (last accessed Dec. 4, 2013).
81
33 U.S.C. § 1311(a)(2006).
82
Animal Feeding Operations (“AFO”) are agricultural operations where animals are kept and raised in confined
situations. Concentrated Animal Feeding Operations (“CAFO”) are Animal Feeding Operations that (i) meet the
definition of AFO; and (ii) meets the regulatory definition of either (a) large CAFO, (b) medium CAFO, or (c) small
CAFO. See http://www.epa.gov.
83
Aquaculture is the farming of aquatic organisms such as fish, crustaceans, mollusks and aquatic plants. Nat’l
Oceanic and Atmospheric Admin., “What is Aquaculture?” available at
http://www.nmfs.noaa.gov/aquaculture/what_is_aquaculture.html (last accessed Dec. 4, 2013).
84
Clean Water Act, Envtl. Prot. Agency, http://www.epa.gov/agriculture/lcwa.html; Nonpoint Source Pollution and
Agriculture. Point source is defined as “any discernable confined and discrete conveyance, including but not limited
to any pipe, ditch, channel, tunnel, conduit, well, discrete fissure, container, rolling stock, concentrated animal
feeding operation, or vessel or other floating craft, from which pollutants are or may be discharged.” 33 U.S.C. §
1362(14)(2006).
85
33 U.S.C. §§ 1311(b)(2)(A), 1311(b)(2)(C).
86
Id.
87
Water Rx, supra n. 47 at 416.
88
Envtl. Prot. Agency, Water: Industry Effluent Guidelines FAQ, available at
http://water.epa.gov/scitech/wastetech/guide/questions_index.cfm (last accessed Dec. 4, 2013).
79
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(i) the cost of achieving the reductions; (ii) the age of equipment and facilities involved; (iii) the
process employed; (iv) potential process changes; and (v) non-water quality environmental
impacts, including energy requirements.89 The EPA’s significant enforcement discretion may
serve as a way for the EPA to regulate the disposal of pharmaceuticals.
(ii) Safe Drinking Water Act
The Safe Drinking Water Act could also be used to regulate the concentration of
pharmaceuticals in the water, but in its current form does not do enough to keep pharmaceuticals
out of the water. The Safe Drinking Water Act empowers the EPA to regulate both naturally
occurring and manmade substances that “may have an adverse effect on the health of persons”90
through implementation of drinking water quality standards.91 The Act requires the EPA to
promulgate standards for listing contaminants, which the EPA then regulates as “listed.”92
Unfortunately, the EPA’s listed contaminants exclude many pharmaceuticals because of the low
concentrations in which they are found in the water.93 However, with increasing concern about
adverse human health effects as a result of pharmaceuticals in the water, the EPA could use the
Safe Drinking Water Act to promulgate standards for keeping pharmaceuticals out of the water
by listing pharmaceutical compounds as drinking water contaminants.
(iii) Resource Conservation and Recovery Act (“RCRA”)
The Resource Conservation and Recovery Act (“RCRA”)94 could also be used to regulate
the disposal of pharmaceuticals, but in its current form is not robust enough to do so. The

89

Id.
Id. at § 300g-1(b)(1)(A)(i); Water Rx, supra n. 47 at 416 (citing 42 U.S.C. § 300f(6)).
91
42 U.S.C. § 300g-1(b)(1)(A) (2006).
92
Melanie Leitman, supra n. 47 at 416.
93
Id. at 417 (citing Pharmaceuticals in the Nations Water: Assessing Potential Risks and Actions to Address the
Issue Before the S. Comm. on Env’t. and Public Works, (Apr. 15, 2008) (statement of Benjamin H. Grumbles),
available at http:// epw.senate.gov/public/index.cfm?FuseAction=Files.View&FileStore_id=7f39d92b-3089-47039063-e5d6c1381332 (last accessed Dec. 4, 2013)).
94
42 U.S.C. § 6901 et seq.
90
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disposal of solid waste is regulated through RCRA, the purpose of which is to “promote the
protection of health and the environment and to conserve valuable material and energy
resources.”95 However, despite the express inclusion of a number of types of medical waste,
unused or expired pharmaceuticals fit only within the catchall provision of RCRA.96 RCRA
exempts domestic sewage or any other substance from a domestic source from the regulation,97
and therefore exempts pharmaceutical waste from domestic sources.98
The statute also includes provisions for the management of hazardous waste99 and a
program for tracking medical waste.100 In the chapter, Congress declares it to be national policy
of the United States that “wherever feasible, the generation of hazardous waste is to be reduced
or eliminated as expeditiously as possible...to minimize the present and future threat to human
health and the environment.”101 This chapter is to be integrated with the Clean Water Act102 to
the extent that it can be done in a “manner consistent with the goals and policies” of both the
Solid Waste Disposal Act and the Clean Water Act.103 Within this chapter, “hazardous waste” is
defined as:
A solid waste, or combination of solid wastes which because of its quantity,
concentration, or physical, chemical or infectious characteristics may –
(a) Cause, or significantly contribute to an increase in mortality or an increase in serious,
irreversible, or incapacitating reversible, illness; or
(b) Pose a substantial present or potential hazard to human health or the environment
when improperly treated, stored, transported, or disposed of, or otherwise
managed.104
95

42 U.S.C. § 6902(a).
The catchall exception reads, “Such other waste material that results from the administration of medical care to a
patient by a health care provider and is found by the Administrator to pose a threat to human health or the
environment.” § 6902a(a)(11).
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This definition is broad and could potentially include within its scope a number of different types
of waste; the definition of “medical waste” narrows its scope. Medical waste is defined as, “any
solid waste, which is generated in the diagnosis, treatment or immunization of human beings or
animals, in research pertaining thereto, or in the production or testing of biologicals.”105 In
Subchapter X, the definition of medical waste is further narrowed.106
RCRA categorizes hazardous waste into four lists, the P-list, the F-list, the K-list and the
U-list.107 RCRA does list some pharmaceutical compounds on its P-list and U-list as wastes,108
and therefore hospitals and skilled nursing facilities are subject to its provisions.109 However, the
RCRA hazardous waste lists have not been substantially updated, and the enforcement of the
regulations against hospitals and skilled nursing facilities is challenging, as the lists were not
originally intended for regulation of the health-care industry.110
As they currently stand, the Clean Water Act, the Safe Drinking Water Act, and RCRA
are inadequate to address the growing problem of pharmaceutical waste in the water.
B. FDA
The FDA has its own approach to the regulation of pharmaceuticals in the environment.
While the FDA’s role is to protect public health rather than the environment,111 the analysis of

105

§ 6903(40).
42 U.S.C. § 6992a(a).
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40 C.F.R. 261
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40 C.F.R. § 261.33
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Fish on Morphine, supra n. 7 at 150-51.
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Id. at 150 (citing Ron Seely, Flushed Drugs Polluting Water; Complicated Rules for Disposal Result in Most
Hospitals Taking Easy Way Out, Wis. St. J., Dec. 10, 2006).
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Food and Drug Administration, About FDA, available at
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194877.htm (last accessed Dec. 4, 2013) (“FDA is
responsible for protecting public health by assuring that foods are safe, wholesome, sanitary and properly labeled;
ensuring that human and veterinary drugs, and vaccines, and other biological products and medical devices intended
for human use are safe and effective”).
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the Food, Drug and Cosmetic Act112 is useful in understanding the FDA’s approach to
pharmaceutical waste entering the environment.

(i) Federal Food, Drug & Cosmetic Act (“FDCA”)
In its current form, the FDCA is inadequate to regulate the disposal of drugs into water
sources, because it requires that the FDA prioritize human health over environmental
concerns.113 The goals of the FDCA are to assure that foods are safe for human consumption;
that drugs and medical devices are safe and effective for human use; and that cosmetics are
safe.114 New drugs seeking market approval must undergo a rigorous evaluation process prior to
entry into interstate commerce.115 The approval criteria do not include environmental
considerations.116 However, drug residue in drinking water may pose a risk to human health, as
humans are exposed to these drugs by drinking the water. Thus, within the scope of the FDCA,
the FDA may be able to find the authority to investigate the impact that pharmaceuticals in the
water will have on human health.
The EPA has a small stake in the FDCA, as they are given the authority to set maximum
residue limits for pesticide residue on food.117 While this is not related to the disposal of
pharmaceutical waste into the water, the provision could be expanded to set residue limits for
pharmaceutical residue in the water. The inclusion of the EPA’s regulatory authority in the
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21 U.S.C. § 301 et seq.
Water Rx, supra n. 47 at 410.
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http://www2.epa.gov/laws-regulations/summary-federal-food-drug-and-cosmetic-act (last accessed Dec. 4, 2013).
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FDCA is indicative of the fact that Congress has previously contemplated joint action between
the FDA and the EPA. Within the scope of the FCDA, the EPA and the FDA may be able to
create a regulatory framework that addresses the disposal of pharmaceuticals in the water.

(ii) National Environmental Policy Act (“NEPA”)
The National Environmental Policy Act (“NEPA”) provides a useful framework for the
design of a new environmental assessment program for the disposal of pharmaceutical wastes.
However, as it currently stands, NEPA is inadequate because the FDA has determined
pharmaceuticals to be exempt from NEPA’s requirements. NEPA was enacted to require federal
agencies to investigate the environmental impact of their activities before undertaking a certain
action.118 NEPA requires all federal agencies to “use all practicable means to create and maintain
conditions under which man and nature can exist in productive harmony.”119 Government
agencies satisfy this requirement by undertaking to prepare detailed statements (“environmental
impact statements”) that assess the environmental impact of their actions.120 Environmental
impact statements are required only after an environmental assessment determines that
significant environmental harm is likely to result from the action.121
The preparation of environmental impact statements requirement is waived for certain
actions, which the respective agency has determined do not significantly affect the
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environment.122 To be excluded means that the action does not require the preparation of either
an environmental assessment or an environmental impact statement prior to taking the action.123
One such exclusion made by the FDA is the categorical exclusion of pharmaceuticals with a
concentration of less than one part per billion at the point of entry into the environment.124
Substances that “occur naturally in the environment” are also excluded.125 This exclusion is not
broad enough to cover all pharmaceuticals; some new drug applications are required to conduct
an environmental assessment and determine whether an environmental impact statement is
necessary.126 Conversely, certain chemicals enter the environment in very low concentrations –
parts per trillion – but even at such low concentrations have a significant impact on the
environment and on animal health.127 The FDA has the discretion to amend or rewrite the
exclusion to require an environmental assessment for all new drug applications. To do so would
be a significant step in understanding the impact that the disposal of pharmaceuticals has on the
environment.
III. Proposed Solutions
The problem of pharmaceutical waste in the water is not a new one, and for many years
scientists and agencies have worked to develop ways to solve this problem. Regulators have
proposed a number of solutions, but none quite accomplish the goal of reducing the amount of
pharmaceutical waste in the waters. The best practices fliers put out by the EPA and the FDA are
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inadequate because they do not impose binding requirements on consumers, and are not properly
publicized to ensure consumer awareness. The pharmaceutical take-back programs have yielded
great results, but are not held often enough to be effective. Finally, Congresswoman Slaughter’s
pharmaceutical stewardship program, which had great potential, was not enacted.
Best Practices Fliers. Pharmacies and practitioners that are registered with the Drug
Enforcement Agency (“DEA”) must follow certain guidelines for disposal of unused controlled
substances.128 However, for the general public, the regulations are less clear. The FDA and the
EPA have separately determined the best practices for disposal of unused pharmaceuticals. In
2009, EPA issued a flier, which ranked and explained the best practices for disposing of
pharmaceuticals.129 This flier explicitly rejects flushing pharmaceuticals in the toilet, and ranks
returning unused drugs to the pharmacy over other domestic disposal practices.130 The FDA, on
the other hand, suggests that consumers with unused drugs dispose of them in the trash.131
Further, for certain drugs, the recommended disposal practice is flushing the unused
pharmaceuticals down the toilet.132 This disparity in accepted disposal practices is pervasive, and
leads to consumer confusion, which is why a joint action plan would be useful.
Returning Unused Drugs/Pharmaceutical Take-Back Programs. In the 111th
Congressional session,133 a number of bills addressed the issue of pharmaceutical disposal and
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contamination, though none of the bills passed.134 One such bill proposed a pharmaceutical takeback program, which would require state or local government agencies to provide a mechanism
through which consumers can return unwanted medicines.135 A number of states have created
programs in which consumers can mail back136 or drop off137 their unused or unwanted
pharmaceuticals and over-the-counter medications.
Despite a failure to pass these bills, the DEA implemented a national drug take-back
program in 2010.138 The most recent program was held in October 2013 and yielded almost 700
thousand pounds of unused and expired pharmaceuticals.139 During the latest take-back program,
there were over 5,000 take-back locations across all 50 states and the District of Columbia.140
These take-back days are vitally important, as the DEA heavily regulates the people and entities
authorized to handle controlled substances.141
However, despite the vastness of the DEA’s drug take-back program, and the fact that
there have been seven take-back days in the last three years,142 the sheer volume of drugs
returned in the most recent take-back day indicates that more needs to be done. Considering the
extremely high number of prescriptions written per year,143 it is likely that a significant number
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of prescription drugs were not returned.144 Further, for consumers worried about their children
or other members of their household abusing leftover prescription drugs, bi-annual take-back
programs are too infrequent, requiring these consumers to choose a different disposal method.
Take-back programs are valuable and likely contribute significantly to the goal of decreasing the
amount of pharmaceutical waste in the water, but are inadequate as currently implemented.
Pharmaceutical Stewardship Program – H.R. 2939. In 2011, Congresswoman Louise
Slaughter proposed the Pharmaceutical Stewardship Program, which introduces a way to safely
dispose of pharmaceuticals and “ensure that they are kept out of drinking water and out of the
hands of unsuspecting children or criminals.”145 The bill proposed the creation of a private, notfor-profit corporation, financed by pharmaceutical companies, which would be responsible for
creating drug take-back programs in every state.146 The bill also proposed the creation of a
commission tasked with developing a “strategy to prevent pharmaceutical contaminants from
polluting our waterways and environments from production to disposal.”147 The bill was not
passed in the 112th Congressional session,148 though had it been passed, it would have been
integral in reducing the amount of domestically used pharmaceuticals disposed of in the water.
IV. Proposed Joint Action Plan between EPA and FDA
Previous actions attempting to curb the amount of pharmaceuticals in our waters have
been inadequate; a lack of uniformity in approaches and a lack of widespread knowledge
contribute to the inability to properly regulate. This section proposes a joint action plan in which
the EPA and the FDA work together to develop a single regulatory approach to the disposal of
144
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pharmaceuticals. Creating an entirely new regulatory structure to address a singular problem
would be cumbersome and likely unnecessary, so, regulatory agencies should operate under
framework of existing regulations. The joint action plan involves reworking and strengthening
current regulatory structures to include the disposal of pharmaceutical compounds within their
scope. Once the current regulations are expanded to include the disposal of pharmaceuticals, the
creation of a required NEPA-like environmental assessment will be implemented. This will shift
the burden of investigating disposal practices and evaluating their environmental impact to the
pharmaceutical companies. This burden shift is important because it places the financial burden
of investigation on the pharmaceutical companies rather than the federal government, and would
eliminate ex post facto examinations of toxicity. The EPA would no longer have to deal with the
pharmaceutical waste’s effects on the environment and aquatic wildlife after the waters were
already polluted. This joint action plan will allow the FDA and the EPA to monitor the
environmental effects of a drug long before the drug pollutes our waters.
A. Creation of a More Robust Regulatory Framework
The Clean Water Act already regulates the discharge of pollutants by point sources into
the water. The EPA should write a new regulation that includes as point sources all major
contributors to the discharge of pharmaceutical waste water sources. The Clean Water Act
includes pharmaceutical manufacturing plants149 as regulated point sources.150 Under the new
regulation, hospitals, long term care facilities and other acute care facilities should be considered
point sources of pharmaceutical waste discharge. This will subject other major polluters151 to
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EPA regulation and investigation.152 RCRA already regulates hospitals and skilled nursing
facilities’ discharge of P-list and U-list wastes,153 and requires integration with the Clean Water
Act. Thus, the EPA can use the hazardous waste disposal requirements under RCRA as a
framework, but include more pharmaceuticals on these lists. Alternatively, a new list can be
created that lists pharmaceutical compounds that are commonly discharged by hospitals and
skilled nursing facilities.
Once these polluters are included under the Clean Water Act umbrella, the EPA has the
ability to enforce best available technology standards. The EPA and the FDA should jointly
create a task force that includes members of both environmental protection groups and public
health groups to determine the best available technology for the discharge of pharmaceutical
pollutants. Since technology is always evolving and changing, the task force should reevaluate
annually.
The enforcement of the best available technology standard is important as a way to
regulate the disposal of pharmaceuticals that are already on the market by changing disposal
practices to reflect current knowledge about best practices, and creating a regulatory floor that
operates to reduce the amount of pharmaceutical discharge disposed of into the water. Further, a
strong enforcement scheme will be technology forcing, creating incentives for regulated industry
to develop new cost-effective technology to comply with the Clean Water Act requirements. It is
important for the FDA and the EPA to have equal investigatory and enforcement powers to
ensure compliance with the best available technology requirements.
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In revising their regulatory framework, the EPA should also include pharmaceutical
contaminants in its water quality standards under the Safe Drinking Water Act. Under the Safe
Drinking Water Act, the EPA interacts with states to implement water quality standards.154 The
EPA should use this relationship with state agencies to have the states conduct independent
investigations of the pharmaceutical contaminants with the highest concentrations in the state’s
drinking water supply. Including pharmaceuticals as a listed contaminant would force state
agencies to test for pharmaceutical contaminants as a part of the tests currently required under
the Safe Drinking Water Act. The EPA should work with the FDA to determine the
concentration threshold of pharmaceutical contaminants, based on state reports of drinking water
concentrations, necessary to protect public health. Compliance with the Safe Drinking Water Act
is mandatory and subject to legal enforcement,155 thus including pharmaceuticals as listed
contaminants will force states to create mechanisms for reducing the pharmaceutical
contaminants in their drinking water.
B. Environmental Assessment
The final portion of the joint action plan borrows its scheme from the National
Environmental Policy Act. The FDA already has rigorous requirements in order for a drug to be
approved to market.156 However, an assessment of the environmental impact of drugs preapproval is not always conducted or required.157 To remedy this, the FDA and the EPA should
create a joint regulatory scheme which requires an environmental assessment of all new drugs
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seeking market approval, similar to NEPA. The EPA should begin by determining the
pharmaceutical compounds most commonly found in drinking water. The EPA should also
conduct an investigation into each of the disposal methods that they, and the FDA, have
proposed. Investigating the environmental impact of incineration, household solid waste
disposal, and flushing,158 the agencies should jointly set thresholds of environmental impact at
which an environmental impact statement would be required. This list should be given to the
FDA to promulgate a list of newly regulated pharmaceutical compounds. The regulation should
require pharmaceutical companies seeking market approval for new drugs containing these
compounds to conduct an environmental assessment. The environmental assessment should
focus on the impact that disposal of the drug would have on the environment. If the disposal of
the approval-seeking drug surpasses the set threshold, the pharmaceutical company should be
required to conduct an environmental impact statement. The environmental impact statement
should require then pharmaceutical company to conduct an investigation of each of the disposal
methods, and recommend the best practice for disposal. The best disposal practice may be
incineration, solid waste disposal, flushing, return to the pharmacy, or any other method that
pharmaceutical company determines to have the least environmental impact. Conducting an
environmental assessment should be required of all pharmaceutical companies before the drug is
approved to market. The subsequent environmental impact statement and recommendation of
disposal practice should also be required when an environmental assessment reveals the impact
of disposal to be greater than the EPA-determined threshold.
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Based on the pharmaceutical company’s disposal recommendation, the FDA should
change the labeling requirements of pharmaceuticals to require the packaging of pharmaceuticals
to include specific instructions for disposal. In some cases, disposal methods are already required
to be included on drug packaging. However, this is neither an inclusive nor universal
requirement. The FDA should expand the labeling requirement to include all pharmaceuticals.
This should be relatively easy to implement prospectively because the environmental assessment
will already have been conducted.
Lastly, the EPA and the FDA have to act to make it easier for people to return unused or
unwanted pharmaceuticals to pharmacies or hospitals. Rather than having two take-back days a
year, there should be hazardous waste bins in each pharmacy where consumers can return unused
pharmaceuticals at any time. This will require the FDA to further expand the scope of the
Controlled Substances Act to allow all pharmacies to accept the return of controlled substances.
Further, the EPA would be required to determine a way to sort the returned pharmaceuticals in
order to dispose of them in the most environmentally friendly way, and keep these returned
pharmaceuticals out of the water. Lastly, the EPA and FDA would still face the hurdle of
actually getting people to return their unused pharmaceuticals, because for the consumer,
flushing them is more convenient than returning them. This may include the implementation of a
rebate or other sort of benefit plan in which the consumer gains a reward or a rebate for returning
unused pharmaceuticals.159 Through joint action, the EPA and the FDA can create a regulatory
scheme that prospectively limits the amount of pharmaceuticals in the water.
V. Remaining open questions/problems
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While the implementation of a joint action plan is a step in the direction of reducing the
pharmaceutical waste in the water, a number of problems remain unsolved. One remaining
problem is the feasibility of creating an environmental impact statement for disposal of each
newly introduced pharmaceutical. There are a significant number of variables that may impact
the ability for the pharmaceutical company to engage in a comprehensive study of the impact of
disposal in the water. While it would be feasible for the company to engage in a short-term study
of the immediate, or near immediate effects of a concentration of the drug in the water, it will be
difficult to study the long-term effects. This raises the question of the length of time the
environmental impact study should span. A month may be insufficient, but a year may
recklessly or unnecessarily delay the introduction of a drug into the market. This delay of
introduction may adversely affect public health, by restricting people from receiving a
potentially beneficial or therapeutic drug. Finding this balance will be a hurdle that the FDA and
the EPA will have to clear.
A second remaining problem is the dissemination of the information about the proper
disposal technique of a particular pharmaceutical. The results of the environmental impact
statements will vary depending on the pharmaceutical. Thus, the best, and most environmentally
friendly disposal method may also vary depending on the pharmaceutical. This creates the
problem of dissemination of disposal information. Each pharmaceutical bottle should include
information about the proper disposal method, and information about disposal should also be
included in the package insert,160 preferably in the “Highlights” portion.161 The information
160
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about disposal can be included on the bottle, underneath the dosage information. It is most likely
to be seen by patients if the information is put on the bottle. As an alternative, the package insert
can, and should, include information about proper practice for disposing of the drug. However, it
is unlikely that a majority of patients look at the information. Further, it is unlikely that a
majority of patients consider proper disposal of their pharmaceuticals germane enough to check
the package insert for information about proper disposal. Thus, there would need to be notices
placed in ways that they would reach a significant number of people. These notices would need
to inform patients that proper disposal information is included in the package insert. Including
disposal information in the package insert would also require prescribing physicians to inform
patients to check the proper disposal method in the package insert. The dissemination of
information remains a problem because despite the FDA’s and the EPA’s efforts to reduce the
amount of pharmaceuticals in the water by requiring an environmental impact statement
regarding the disposal of the pharmaceutical, if patients do not cooperate with the disposal
requirements, the pharmaceuticals may still end up in the water.
Finally, this solution does not address the problem of pharmaceutical waste that is already
in the water. While it may curb the disposal of future pharmaceuticals being disposed of in our
nation’s waters, there are still billions of prescriptions being written each year for
pharmaceuticals that are already approved. In order for this to make a significant change, the
FDA and the EPA must retroactively apply the environmental impact statement and labeling
requirements to pharmaceuticals that are already market-approved. This would come at extreme
cost to pharmaceuticals companies and would likely be difficult to enforce.
Conclusion
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It is unlikely that worldwide dependence of pharmaceuticals is on the decline. It is,
therefore, necessary to take regulatory action to stop the disposal of pharmaceuticals in the water.
The FDA and the EPA should work together to develop a regulatory scheme that focuses both on
protecting human health and preserving the environment while requiring pharmaceutical
companies seeking approval for new drugs to bear the burden of developing the proper disposal
practices.
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